Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial

Atte Meretoja(University of Helsinki), Stephen M. Davis(The Royal Melbourne Hospital), Geoffrey Cloud(Monash University), Darshan Shah(Mental Health Research Institute), Leonid Churilov(The University of Melbourne), Christopher Levi(John Hunter Hospital), Gerli Sibolt(Helsinki University Hospital), Nawaf Yassi, Bernard Yan(Centre hospitalier universitaire d'Orléans), Tissa Wijeratne(Sunshine Hospital), Der‐Yang Cho(China Medical University), Timothy Kleinig(Royal Adelaide Hospital), Daniel Strbian(Helsinki University Hospital), Richard I. Aviv(Ottawa Hospital), Christen Barras(The University of Melbourne), Geoffrey A. Donnan(The Royal Melbourne Hospital), Marjaana Tiainen(Helsinki University Hospital), Thanh G. Phan(Monash Health), Jiann‐Shing Jeng(National Taiwan University Hospital), Vincent Thijs(Florey Institute of Neuroscience and Mental Health), Henry Ma(Monash University), Sami Curtze(University of Helsinki), Andrew Moey(Lyell McEwin Hospital), Neil J. Spratt, Peter Mitchell(The Royal Melbourne Hospital), Bruce Campbell(The Royal Melbourne Hospital), Jackson Harvey(Royal Adelaide Hospital), Mark Parsons(UNSW Sydney), Teddy Y. Wu(Christchurch Hospital), Gagan Sharma(The Royal Melbourne Hospital), Chung Y. Hsu(Kaohsiung Medical University), Christopher Bladin, Sung‐Chun Tang(National Taiwan University Hospital)
The Lancet Neurology
October 28, 2020
Cited by 144


Related Papers